Aequus Pharmaceuticals Inc

Company Profile

Aequus Pharmaceuticals Inc had its IPO on under the ticker symbol AQSZF.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Aequus Pharmaceuticals Inc has a staff strength of 14 employees.

Stock update

Shares of Aequus Pharmaceuticals Inc opened at $0.03 at the start of the last trading session i.e. 2023-03-23.

The stocks traded within a range of $0.03 - $0.03, and closed at $0.03.

This is a +40.19% increase from the previous day's closing price.

A total volume of 13,000 shares were traded at the close of the day’s session.

In the last one week, shares of Aequus Pharmaceuticals Inc have increased by +6.38%.

Aequus Pharmaceuticals Inc's Key Ratios

Aequus Pharmaceuticals Inc has a market cap of $2.51 million, indicating a price to book ratio of 32.7765 and a price to sales ratio of 1.4364.

In the last 12-months Aequus Pharmaceuticals Inc’s revenue was $1.86 million with a gross profit of $2.69 million and an EBITDA of $-2437593. The EBITDA ratio measures Aequus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Aequus Pharmaceuticals Inc’s operating margin was -131.1% while its return on assets stood at -41.77% with a return of equity of -291.74%.

In Q3, Aequus Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 51.1%.

Aequus Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aequus Pharmaceuticals Inc’s profitability.

Aequus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 1.6318 and a EV to EBITDA ratio of -1.4378. Its price to sales ratio in the trailing 12-months stood at 1.4364.

Aequus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$2.67 million

Total Liabilities

$2.36 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Aequus Pharmaceuticals Inc ended 2023 with $2.67 million in total assets and $0 in total liabilities. Its intangible assets were valued at $2.67 million while shareholder equity stood at $-363789.00.

Aequus Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $2.36 million in other current liabilities, 23990904.00 in common stock, $-28698948.00 in retained earnings and $0 in goodwill. Its cash balance stood at $764310.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $28961.00.

Aequus Pharmaceuticals Inc’s total current assets stands at $1.28 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $274896.00 compared to accounts payable of $116509.00 and inventory worth $130106.00.

In 2023, Aequus Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Aequus Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.03

52-Week High

$0.0998

52-Week Low

$0.0013

Analyst Target Price

$

Aequus Pharmaceuticals Inc stock is currently trading at $0.03 per share. It touched a 52-week high of $0.0998 and a 52-week low of $0.0998. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.03 and 200-day moving average was $0.04 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 1496.3% of the company’s stock are held by insiders while 0% are held by institutions.